Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib

Ruxolitinib is a Janus kinase (JAK)1 and JAK2 inhibitor approved for the treatment of myelofibrosis and for polycythemia patients who are resistant or intolerant to hydroxyurea. We report a 72 year-old man patient with polycythemia vera who developed multiple cutaneous squamous cell carcinomas (cSCC...

Descripción completa

Detalles Bibliográficos
Autores principales: March-Rodriguez, Álvaro, Bellosillo, Beatriz, Álvarez-Larrán, Alberto, Besses, Carles, Pujol, Ramon M, Toll, Agustí
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992689/
https://www.ncbi.nlm.nih.gov/pubmed/33911570
http://dx.doi.org/10.5021/ad.2019.31.2.204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992689/
https://www.ncbi.nlm.nih.gov/pubmed/33911570
http://dx.doi.org/10.5021/ad.2019.31.2.204

Ejemplares similares